Director adds Encompass Health (NYSE: EHC) shares via fees, dividends

Rhea-AI Filing Summary

Encompass Health Corp director Edward M. Christie III reported acquiring additional company stock on January 15, 2026. He received 9 shares of Encompass Health common stock at $0.00 per share as part of an award of restricted stock units tied to a cash dividend of $0.19 per share, based on a closing price of $102.80.

On the same date, he acquired a further 269 shares at a weighted average price of $102.82 per share through the company’s Directors Deferred Stock Investment Plan, which reinvests deferred director fees and related dividends in common stock. Following these transactions, he directly held 7,182 shares of Encompass Health common stock.

Insider Trade Summary

Net Buyer: 278 shares

Net Buy 2 txns

Insider Christie Edward M III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Encompass Health Common Stock	9	$0.00	$0.00
Grant/Award	Encompass Health Common Stock	269	$102.82	$28K

Holdings After Transaction: Encompass Health Common Stock — 7,182 shares (Direct)

Footnotes (3)

1. F1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.
2. F2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026.
3. F3. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.82 to $102.90, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/16/2026 - 04:18 PM Learn about SEC filing dates

FAQ

What insider transactions did Encompass Health (EHC) report for Edward M. Christie III?

Encompass Health reported that director Edward M. Christie III acquired a total of 278 shares of Encompass Health common stock on January 15, 2026, split between RSU-related shares and purchases under the Directors Deferred Stock Investment Plan.

How many Encompass Health (EHC) shares does the director own after these transactions?

After the reported transactions on January 15, 2026, Edward M. Christie III directly beneficially owned 7,182 shares of Encompass Health common stock.

What was the structure of the 9-share award reported by Encompass Health (EHC)?

The 9-share award came from additional restricted stock units credited in connection with a $0.19 per share common stock dividend, calculated using a closing price of $102.80 on January 15, 2026, and was reported at a price of $0.00 per share.

How were the 269 Encompass Health (EHC) shares acquired under the Directors Deferred Stock Investment Plan?

The 269 shares were acquired through the Directors Deferred Stock Investment Plan, which uses deferred director fees and reinvested dividends to purchase Encompass Health common stock, at a weighted average price of $102.82 per share.

What price range applied to the 269 Encompass Health (EHC) shares purchased?

The 269 shares purchased under the Directors Deferred Stock Investment Plan were bought in multiple transactions at prices ranging from $102.82 to $102.90 per share, resulting in a weighted average price of $102.82.

What dividend information did Encompass Health (EHC) disclose in relation to this Form 4?

Encompass Health disclosed that on January 15, 2026 it paid a common stock dividend of $0.19 per share, and the closing stock price that day was $102.80, which was used to determine additional RSUs credited to non-employee directors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Christie Edward M III

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM AL 35242

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	01/15/2026		A		9(1)	A	$0	6,913	D
Encompass Health Common Stock	01/15/2026		A		269(2)	A	$102.82(3)	7,182	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026.

3. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.82 to $102.90, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

	/s/Patrick Darby, attorney-in-fact for Edward M. Christie, III	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.